Antiaging Quantum Living Inc (AAQL)

[Basin Street Blues]

Bloomberg Professional Just out

Gilead, Achillion Race for New Hepatitis CAnalyst Asthika Goonewardene Dashboard: Biotech, Global (BI BIOTG)Apr 27, 2015 12:36

Achillion and Gilead, competing for next-generation Hepatitis C drugs, presentdata at the European Association for the Sof the Liver (EASL) conference. Both are aggressively pursuing new regimens and combining different classes of drugs that attack replication of the Hep C virus. Of interest was Achillion's Nucleotide NS5B inhibitor, known as Nuc, and next-generation Nonstructural Protein 5inhibitors (NS5A) from both companies.Gilead's data was underwhelming, so Achillion may be winning this contest.
Data presented for Achillion's ACH-3422 underpinned its promise in treating Hep C at last week's EAS15 conference. The Nuc-class drug reduced viral loads even at the end of 14-day therapy, suggesting more room for eradication if the drug is continued. The viral load cleared as a proportion of the baseline also fueled hopes that the duration of therapy can be reduced in multi-drug combinations. Still, eradication while on therapy is insufficient; the drug must also keep the virus suppressed after treatment.